252019-65-1

Usage

Uses

Used in Dye and Pigment Production:
N,N-DIBOC-2-CHLORO-4-NITROANILINE is used as a key intermediate for the production of dyes and pigments due to its chemical properties and reactivity.
Used in Pharmaceutical Industry:
N,N-DIBOC-2-CHLORO-4-NITROANILINE is used as a reagent in the synthesis of pharmaceutical intermediates, contributing to the development of new drugs and medications.
Used in Agrochemical Production:
N,N-DIBOC-2-CHLORO-4-NITROANILINE is also employed in the production of agrochemicals, serving as a building block for the synthesis of various agricultural chemicals.
It is crucial to handle N,N-DIBOC-2-CHLORO-4-NITROANILINE with care due to its toxic nature and potential health hazards if not properly managed.

InChI:InChI=1/C16H21ClN2O6/c1-15(2,3)24-13(20)18(14(21)25-16(4,5)6)12-8-7-10(19(22)23)9-11(12)17/h7-9H,1-6H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 121-87-9 2-Chloro-4-nitroaniline 
• 1122-58-3 dmap 

Downstream Products

• 1309434-78-3 N-(3-chloro-4-(3-methyl-2,5-dioxo-3-phenylpyrrolidin-1-yl)phenyl)picolinamide 
• 1218926-48-7 N-(3-chloro-4-(2,5-dioxo-3-phenylpyrrolidin-1-yl)phenyl)picolinamide 
• 1309434-72-7 N-(3-chloro-4-(1,3-dioxo-2-azaspiro[4.5]decan-2-yl)phenyl)picolinamide 
• 1309434-69-2 N-(3-chloro-4-(3,3-dimethyl-2,5-dioxopyrrolidin-1-yl)phenyl)picolinamide 
• 1309434-82-9 N-(3-chloro-4-((1R,2S,3R,4S)-bicyclo[2.2.2]oct-5-ene-1,3-dioxo-1H-isoindol-1-yl)phenyl)picolinamide 
• 1309434-76-1 N-(3-chloro-4-(bicyclo[2.2.1]hept-5-ene-1,3-dioxo-1H-isoindol-1-yl)phenyl)picolinamide 
• 1341167-65-4 N-(3-chloro-4-((3aR,4R,7S,7aS)-1,3-dioxohexahydro-1H-4,7-epoxyisoindol-2(3H)-yl)phenyl)picolinamide 
• 1309434-86-3 N-(3-chloro-4-((3aR,7aS)-1,3-dioxohexahydro-1H-isoindol-2(3H)-yl)phenyl)picolinamide 
• 1341167-60-9 N-(3-chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl)phenyl)picolinamide 
• 1218926-17-0 N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)picolinamide 
• 1309434-63-6 N-(3-chloro-4-(2,5-dioxopyrrolidin-1-yl)phenyl)picolinamide 
• 1266338-26-4 N-(3-chloro-4-(5-phenylfuran-2-carboxamido)phenyl)picolinamide 
• 1266338-24-2 N-(3-chloro-4-(thiophene-2-carboxamido)phenyl)picolinamide 
• 1266338-23-1 N-(2-chloro-4-(picolinamido)phenyl)thiazole-2-carboxamide 

Relevant academic research and scientific papers

MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu4) with CNS exposure in rats

Herein we report the discovery, synthesis, and evaluation of a series of N-(4-acetamido)-phenylpicolinamides as positive allosteric modulators of mGlu4. Compounds from the series show submicromolar potency at both human and rat mGlu4. In addition, pharmacokinetic studies utilizing subcutaneous dosing demonstrated good brain exposure in rats.

SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION

In one aspect, the invention relates to compounds having a general structure: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); s

Discovery, synthesis, and structure-activity relationship development of a series of N -4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4

There is an increasing amount of literature data showing the positive effects on preclinical antiparkinsonian rodent models with selective positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu4). However, most of the data ge

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity

A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitrile derivatives that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepared. These compounds demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 positive cells compared to our EGFR kinase inhibitor 86 (EKB-569). Three synthetic routes were used to prepare these compounds. They were prepared mostly by acylation of 6-amino-4-(arylamino) quinoline-3-carbonitriles with unsaturated acid chlorides or by amination of 4-chloro-6-(crotonamido)-quinoline-3-carbonitriles with monocyclic or bicyclic anilines. The third route was developed to prepare a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step. We show that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase. We also show the importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramolecular catalysis of the Michael addition. This, along with improved water solubility, resulted in compounds with enhanced biological properties. We present molecular modeling results consistent with the proposed mechanism of inhibition. Binding studies of one compound, 25o (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells. Furthermore, it demonstrated excellent oral activity, especially in HER-2 overexpressing xenografts. Compound 25o (HKI-272) was selected for further studies and is currently in phase I clinical trials for the treatment of cancer.

Use of compounds for the elevation of pyruvate dehydrogenase activity

The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs: wherein: Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within; R1is an ortho substituent as defined within; n is 1 or 2; A—B is a linking group as defined within; R2and R3are as defined within; R4is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.